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ABSTRACT
Introduction: There is scant real-world
information on switching treatment for
anemia associated with chronic kidney disease
(CKD) from methoxy polyethylene glycol-
epoetin beta (PEG-Epo) to darbepoetin alfa
(DA). TRANSFORM was a multi-center,
observational study designed to describe the
time course of hemoglobin (Hb) concentration
(primary outcome measure) and other
parameters of clinical management of anemia
in European hemodialysis patients in clinical
practice before and after a switch from PEG-Epo
to DA.
Methods: Eligible subjects were adult patients
with CKD dialyzed at European dialysis centers
for C26 weeks and treated with PEG-Epo for
C14 weeks immediately prior to being switched
to DA and no earlier than January 2011.
Erythropoiesis-stimulating agent doses and Hb
values were recorded for the 14-week pre-switch
and 26-week post-switch periods.
Results: Of the 1,027 eligible patients enrolled
at 42 hemodialysis centers in 7 European
countries, 785 were included in analyses.
Mean (95% confidence interval [CI]) Hb was
generally stable: 11.19 (11.11, 11.26), 11.48
(11.40, 11.57), and 11.29 (11.20, 11.37) g/dL at
month -1 pre-switch and months 3 and 6
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post-switch, respectively. The geometric mean
(95% CI) PEG-Epo dose at month -1 was 27.4
(26.0, 28.8) lg/week; DA dose was 29.4 (27.9,
30.9), 23.3 (21.9, 24.9), and 25.6 (24.1, 27.1) lg/
week at months 1, 4, and 6, respectively. The
geometric mean (95% CI) dose ratio at
switching was 1.06 (1.01, 1.11). When
stratifying by dose-ratio categories \0.8,
0.8–1.2, and [1.2 at switching, mean DA dose
and Hb converged within narrow ranges by
month 6 post-switch: 23.9–27.0 lg/week and
11.1–11.5 g/dL, respectively. Hb excursions
\10 g/dL were less frequent post-switch versus
pre-switch.
Conclusion: Mean Hb values remained within a
narrow range following switching from PEG-
Epo to DA in this population of hemodialysis
patients. Time trends of mean Hb and DA dose
indicate that physicians titrated DA doses post-
switch, to attain Hb concentrations comparable
to those attained pre-switch with PEG-Epo.
Funding: Amgen (Europe) GmbH, Zug,
Switzerland.
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INTRODUCTION
Anemia is a complication of chronickidney disease
(CKD), and is twice as common in patients with
any stage of CKD as in the general population [1].
Anemia of CKD increases in prevalence and
severity as kidney function declines [2], with over
90% of patients who progress to renal replacement
therapy becoming anemic [3].
Anemia of CKD results primarily from
decreased production of endogenous
erythropoietin (EPO) by the kidneys [4]. There
is a clear clinical rationale for correcting low
hemoglobin (Hb) levels in patients with CKD, as
persistent anemia is associated with increased
risk of cardiac complications and mortality and
impaired quality of life [5–7]. The introduction
of exogenous erythropoiesis-stimulating agents
(ESAs) to clinical practice transformed the care
of patients with CKD by ameliorating anemia,
reducing transfusion requirements and
improving quality of life [8].
The first-generation recombinant ESAs
(epoetin alfa and beta) were short-acting,
generally requiring administration three times
per week [9]. While short-acting originator
(and, more recently, their biosimilar) ESAs
remain available, using the subsequently
developed longer-acting ESAs, which require
less frequent dosing, appears to reduce the
burden of administration on patients,
caregivers and healthcare professionals [10].
The two longer-acting ESAs, darbepoetin alfa
(DA) and methoxy polyethylene glycol-epoetin
beta (PEG-Epo), combine a significantly
increased half-life with a lower binding affinity
for the EPO receptor, allowing them to
stimulate erythropoiesis for longer periods and
to be administered less frequently [9, 11]. DA,
launched in 2001, has five N-linked
oligosaccharide chains rather than the three
contained in short-acting epoetins, conferring
an approximately threefold longer serum half-
life and mean residence time, and is approved
for administration to hemodialysis patients
once a week (QW) or once every 2 weeks
(Q2W) [9, 11, 12]. Compared with epoetin
beta, PEG-Epo, launched in 2009, has an
increased serum half-life that is due to the
addition of methoxy polyethylene glycol (PEG),
and is approved for administration to patients
on dialysis Q2W or once a month (QM) [9, 11,
13].
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When switching patients from short-acting
ESAs to DA or PEG-Epo, clinicians have
reference to the dose conversion schedules
recommended in the DA and PEG-Epo labels
[12, 13]. The PEG-Epo label also provides
recommended dose ranges when converting
patients from DA to PEG-Epo [13], and Hb and
dose data for patients switching from DA to
PEG-Epo are available from randomized clinical
studies [14, 15] and from observational studies
in routine clinical practice [16]. In contrast,
there is no label guidance on switching patients
from PEG-Epo to DA, and to our knowledge
only a single study, published only in abstract
form, has examined outcomes associated with
switching from PEG-Epo to DA [17]. The
objectives of the Observational Cohort Study
of Aranesp Use in EU Haemodialysis Patients
Switched From Mircera (TRANSFORM) study
were primarily to describe the time course of Hb
concentration in EU hemodialysis patients in
real-world clinical practice switched from PEG-
Epo to DA, and secondarily to describe other
parameters of clinical management of anemia
in this group of patients.
METHODS
The TRANSFORM study was designed as a
longitudinal cohort analysis of hemodialysis
patients switched from PEG-Epo to DA. Data
collection for the pre-switch period was entirely
retrospective, while data collection for the post-
switch period could have been either fully
retrospective or partly prospective depending
on whether or not the 26-week post-switch
period had been completed by the date of site
initiation. The study was entirely non-
interventional, with no intention to alter the
clinical management of the enrolled patients.
To ensure that the switch from PEG-Epo was
independent of a site’s participation in the
TRANSFORM study, each site was informed of
the study and approached for enrollment only
after it had been confirmed that switching of
potential study subjects was complete at that
site. This article does not contain any
experimental studies with human or animal
subjects performed by any of the authors.
Eligible subjects were adult (aged 18 years or
over) hemodialysis patients with CKD, who
were switched from PEG-Epo to DA during or
after January 2011. Patients were required to
fulfill the following additional inclusion
criteria: receiving hemodialysis at a European
dialysis center for at least 26 weeks immediately
prior to switching from PEG-Epo to DA;
treatment with PEG-Epo for at least 14 weeks
immediately prior to being switched to DA;
receipt of at least 1 dose of DA post-switch; and
provision of written informed consent,
according to local requirements. Patients were
excluded if they had: been administered more
than 2 doses of an ESA other than PEG-Epo in
the 7 to 14 weeks immediately prior to
switching from PEG-Epo to DA, and/or an ESA
other than PEG-Epo during the 6 weeks
immediately prior to switching to DA; received
chemotherapy during the 14 weeks prior to the
switch; undergone major surgery within
14 weeks prior to the switch; or received a red
blood cell (RBC) transfusion within 14 weeks
prior to the switch.
Each enrolling dialysis center was expected
to enroll a minimum of 20 patients into the
study. The overall study recruitment target was
approximately 1,000 patients, and all subjects
were enrolled between August 28, 2012 and July
3, 2013.
Data on clinical and laboratory parameters
relating to CKD management were abstracted
from patient records and entered by study
center staff into an anonymized study-specific
central database using an electronic case report
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form provided by the study sponsor, Amgen
(Europe) GmbH. Data were collected from
14 weeks prior to the switch from PEG-Epo
until 26 weeks post-switch, regardless of
whether subjects remained on DA or
converted to an alternative therapy. Data
capture ceased at the date of kidney
transplant, death or loss to follow-up if these
occurred before week 26 post-switch. Data were
checked for impossible or implausible values by
an automatic review program built into the
database software.
The primary outcome measure of the
TRANSFORM study was Hb concentration at
monthly intervals. Secondary outcome
measures included PEG-Epo and DA doses over
time, the dose ratio of DA to PEG-Epo at
switching, and the incidence of Hb excursions
below 10 g/dL and above 12 g/dL. These Hb-
concentration thresholds were selected for
examination of Hb excursions because
10–12 g/dL is the target Hb range according to
the guidance in the product labels for both PEG-
Epo and DA [12, 13], and this target range is
incorporated in the position statement on
anemia management in CKD of the European
Renal Best Practice Advisory Board [18]. Results
were analyzed for all patients as well as for
patient subgroups stratified by DA:PEG-Epo
dose ratio at the time of switching in the
following three categories: \0.8, 0.8–1.2 and
[1.2. Data on administration of intravenous
(IV) iron supplements and iron repletion
(transferrin saturation [TSAT] and serum
ferritin) were also collected.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study where applicable according to local
requirements.
Statistical Methods
As no formal hypothesis was tested in this
study, all analyses were descriptive; no tests of
statistical significance were performed. Average
Hb values were reported using arithmetic
means, and mean weekly ESA doses were
reported using geometric means due to the
skewed nature of the dosing data. Two-sided
95% confidence intervals (CIs) were calculated
for mean Hb and weekly ESA doses.
The dose ratio at switching for each subject
was calculated by subtracting the log-
transformed weekly dose of PEG-Epo at switch
from the log-transformed weekly first dose of
DA. The geometric mean dose ratio was derived
from the exponential of the arithmetic mean of
the log-transformed dose ratio.
Analyses were conducted for all eligible
enrolled subjects who received at least one
dose of DA, completed 26 weeks post-switch
on DA, did not receive another ESA during this
period, and had at least one Hb measurement
per month recorded for a minimum of any
4 months post-switch. Any Hb values from
samples drawn within 14 weeks after a RBC
transfusion were excluded from analysis. Results
are presented for observed data, with no
imputation of missing values. Data from this
study were analyzed using SAS Statistical
Software v9.2 (SAS Institute Inc., Cary, NC,
USA).
RESULTS
A total of 1,027 eligible patients were enrolled at
42 hemodialysis centers in seven European
countries; more than half (56%) in France
(Table 1). Of the 1,027 patients enrolled, 785
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(76.4%) were included for analysis. Reasons for
exclusion from the analysis set are presented in
Fig. 1. The dates of the first and last ESA switch
in the cohort were January 26, 2011 and
January 30, 2013, respectively. The baseline
(i.e., at time of switch) demographic and
clinical characteristics of patients included in
the analysis are shown in Table 2. The median
patient age was 72 (Q1 60, Q3 79) years; 43.8%
of patients were female. Approximately, three-
quarters (76.4%) of these CKD patients had
hypertension; more than a third (39.1%) had
diabetes, a quarter (25.0%) had peripheral
vascular disease and almost a quarter (24.1%)
had coronary artery disease. A history of renal
transplantation was reported for 8.2% of
patients. Median duration of hemodialysis was
32.0 (Q1 16.0, Q3 57.0) months.
The primary outcome measure, Hb
concentration, was generally stable in the
post-switch period, rising by less than 0.3 g/dL
in the overall cohort from month -1 (i.e., the
Table 1 Patient geographic distribution
Country Centers, n All enrolled patients
(N5 1,027)
n % of cohort
Belgium 6 190 18.5
France 22 579 56.4
Germany 6 77 7.5
Greece 2 22 2.1
The Netherlands 1 60 5.8
Spain 4 98 9.5
Switzerland 1 1 0.1
Fig. 1 Disposition of patients. Asterisk not mutually exclusive. DA darbepoetin alfa, ESA erythropoiesis-stimulating agent,
Hb hemoglobin
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month pre-switch, when patients were
receiving PEG-Epo) to month 3 following the
switch to DA, then returning towards pre-
switch levels by month 6 post-switch (Fig. 2):
mean (95% CI) Hb was 11.19 (11.11, 11.26) g/
dL, 11.48 (11.40, 11.57) g/dL, and 11.29 (11.20,
11.37) g/dL at months -1, 3, and 6,
respectively.
As shown in Fig. 2, the subgroup analysis
stratified by ESA dose ratio at switch revealed
that the change in mean monthly Hb
concentration in the post-switch period was
driven by patients’ dose ratio at switching.
Whereas the elevation in mean monthly Hb
concentration at month 3 post-switch was
greatest in patients with a dose ratio of [1.2,
this trend was reversed in patients with a dose
ratio at switch of \0.8, with mean monthly Hb
declining from the time of switching to month
4 before rising again to month 6 post-switch.
Mean monthly Hb concentration for patients





Mean (SD) 68.7 (14.3)
Median (Q1, Q3) 72.0 (60.0, 79.0)
Gender, female, n (%) 344 (43.8)
Clinical characteristics
Comorbidities, n (%)a
Coronary artery disease 189 (24.1)
Stroke 41 (5.2)
Transient ischemic attack 41 (5.2)
Myocardial infarction 63 (8.0)
Heart failure 113 (14.4)
Hypertension 600 (76.4)
Peripheral vascular disease 196 (25.0)
Diabetes 307 (39.1)
Any malignancy 105 (13.4)




Duration of dialysis (months)
Mean (SD) 42.9 (40.1)
Median (Q1, Q3) 32.0 (16.0, 57.0)
Hemodialysis access, n (%)
Arteriovenous ﬁstula 606 (77.2)
Arteriovenous graft 38 (4.8)
Permanent venous catheter 124 (15.8)
Temporary venous catheter 11 (1.4)
Other 6 (0.8)
Weekly PEG-Epo dose (lg),






Mean (SD) 11.15 (1.10)
Categories, n (%)
\10.0 108 (13.8)
C10.0 to\12.0 475 (60.5)
C12.0 186 (23.7)
Missing 16 (2.0)
CI conﬁdence interval, Hb hemoglobin, PEG-Epo methoxy
polyethylene glycol-epoetin beta, Q1 ﬁrst quartile, Q3 third
quartile, SD standard deviation
a Categories are not mutually exclusive
b Last PEG-Epo dose is divided by the number of days
between receiving that dose and the subsequent dose, then
multiplied by 7 to convert to a weekly dose; implausible
weekly doses[150 lg were excluded
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with a dose ratio of 0.8–1.2 was roughly parallel
to that of the overall cohort. Notably, despite
these differences in mean monthly Hb between
dose-ratio subgroups, Hb concentration
converged by the end of the post-switch
period; by month 6, mean Hb concentration
was within the range of 11.1–11.5 g/dL across
all three dose-ratio subgroups.
Trends in post-switch DA dosing were
roughly the opposite of the trends seen for Hb
concentration. In the overall cohort, the
geometric mean weekly dose of DA was
highest at 1 month post-switch and fell to
below pre-conversion dosing levels by month
3 (Fig. 3). The geometric mean (95% CI) PEG-
Epo dose at month -1 was 27.4 (26.0, 28.8) lg/
week, with ESA dose rising to a peak at month 1
with a DA dose of 29.4 (27.9, 30.9) lg/week,
then declining to 23.3 (21.9, 24.9) lg/week at
month 4 and reaching 25.6 (24.1, 27.1) lg/week
at month 6.
In the subgroup analysis stratified by dose
ratio at switching, the reduction in geometric
mean weekly dose observed from month 1 to
month 3 was greatest in patients with a dose ratio
of [1.2 (Fig. 3). The trend in geometric mean
weekly DA dose for patients with a dose ratio of
0.8–1.2 was similar to that of the overall cohort.
In contrast, geometric mean weekly DA doses for
patients with a dose ratio\0.8 did not show the
same U-shaped trend as for the other dose-ratio
categories, but instead increased over the post-
switch period. By month 6, geometric mean DA
dose was within the range of 23.9–27.0 lg/week
across all three dose-ratio subgroups.
Overall, the geometric mean (95% CI) dose
ratio at switching was 1.06 (1.01, 1.11), and
more than three-quarters of patients (77.8%)
had a dose ratio of C0.8 (Table 3). By month 6,
the geometric mean (95% CI) dose ratio had
decreased to 0.88 (0.83, 0.93), and the
proportion of patients with a dose ratio of
C0.8 had dropped to 63.0%. As shown in Fig. 4,
there was considerable variability in dose ratio
at switch across countries, with geometric mean
(95% CI) dose ratio at switch ranging from 0.72
(0.57, 0.90) in the Netherlands to 1.36 (1.17,
1.59) in Spain.
Fig. 2 Hemoglobin levels during the observation period
for all patients and stratiﬁed by DA:PEG-Epo dose ratio at
switch. Values are arithmetic means with 95% conﬁdence
intervals. DA darbepoetin alfa, Hb hemoglobin, PEG-Epo
methoxy polyethylene glycol-epoetin beta
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As reported in Table 4, Hb concentration
excursions below the target range (i.e., \10 g/
dL) were generally less frequent in the post-
switch period compared to the pre-switch
period. Hb excursions above the target range
(i.e., [12 g/dL) were slightly more frequent
Table 3 Dose ratio at switch and month 6
PEG-Epo DA
At switch At month 6
Mean weekly dose (lg/week)a
n 768 775 769
Geometric mean (95% CI) 27.83 (26.36, 29.37) 29.99 (28.39, 31.68) 25.57 (24.14, 27.09)
Dose ratiob
n 785 770
Geometric mean (95% CI) 1.06 (1.01, 1.11) 0.88 (0.83, 0.93)
Dose-ratio categories, n (%)
\0.8 174 (22.2) 285 (37.0)
0.8–1.2 310 (39.5) 240 (31.2)
[1.2 301 (38.3) 245 (31.8)
Endpoints were summarized using geometric means
CI conﬁdence interval, DA darbepoetin alfa, PEG-Epo methoxy polyethylene glycol-epoetin beta
a Mean weekly doses were calculated per patient by calculating a mean daily dose for the interval (by dividing each dose
evenly between the days bounded by its date of administration and the day before the next dose, then taking a mean of these
partial doses for the days in the interval) and multiplying by 7 to convert to a weekly dose; implausible weekly doses
[150 lg were excluded
b Mean weekly dose for the ﬁrst DA dose divided by the mean weekly dose of PEG-Epo at switch
Fig. 3 Weekly erythropoiesis-stimulating agent dose during
the observation period for all patients and stratiﬁed by
DA:PEG-Epo dose ratio at switch. Values are geometric
means with 95% conﬁdence intervals. DA darbepoetin alfa,
PEG-Epo methoxy polyethylene glycol-epoetin beta
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during the middle of the post-switch period
compared to the pre-switch period, but by
month 6 had dropped to a similar incidence as
had been observed pre-switch (Table 4).
Use of IV iron supplementation increased
steadily from 67% of subjects at month -3 to
81% by month 3, and then declined to 71% by
month 6. The most common iron preparation
was saccharated iron oxide, administered to
over 80% of subjects receiving IV iron
supplementation. Mean weekly iron dose
ranged from 255 mg at month -3 to 218 mg
Fig. 4 DA:PEG-Epo dose ratio at switch [average weekly
dose of the ﬁrst DA dose divided by the average weekly dose
of PEG-Epo at switch (i.e., lg DA per 1 lg PEG-Epo)] by
country. Values are geometric means with 95% conﬁdence
intervals. Dose ratio for the only patient in Switzerland was
1.0. DA darbepoetin alfa, PEG-Epo methoxy polyethylene
glycol-epoetin beta
Table 4 Hemoglobin excursions\10.0 and[12.0 g/dL
Patients with ‡1 Hb excursion
<10 g/dL >12.0 g/dL
n % (95% CI) n % (95% CI)
PEG-Epo
Month -3 132 16.8 (14.3, 19.6) 228 29.0 (25.9, 32.4)
Month -2 139 17.7 (15.1, 20.6) 228 29.0 (25.9, 32.4)
Month -1 123 15.7 (13.2, 18.4) 195 24.8 (21.9, 28.0)
DA
Month 1 140 17.8 (15.2, 20.7) 181 23.1 (20.2, 26.2)
Month 2 107 13.6 (11.3, 16.2) 230 29.3 (26.1, 32.6)
Month 3 92 11.7 (9.6, 14.2) 260 33.1 (29.8, 36.5)
Month 4 108 13.8 (11.4, 16.4) 256 32.6 (29.3, 36.0)
Month 5 96 12.2 (10.0, 14.7) 218 27.8 (24.7, 31.0)
Month 6 115 14.6 (12.2, 17.3) 208 26.5 (23.4, 29.7)
CI conﬁdence interval, DA darbepoetin alfa, Hb hemoglobin, PEG-Epo methoxy polyethylene glycol-epoetin beta
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at month -1, and was 261 mg at month 6.
Mean TSAT was 28.9% in the 3 months pre-
switch, 26.9% over months 1–3, and 27.6%
over months 4–6. Mean serum ferritin was
487.9 lg/L in the 3 months pre-switch,
459.3 lg/L over months 1–3, and 509.6 lg/L
over months 4–6.
DISCUSSION
The primary finding of this observational
cohort analysis of hemodialysis patients
switched from PEG-Epo to DA in real-world
clinical practice was that, overall, stable Hb
concentrations were maintained over the post-
switch period, with Hb values at month 6 for
patients receiving DA very similar to those in
the month pre-switch when patients were
receiving PEG-Epo. Although changes in Hb
concentration were observed across the post-
switch period, mean monthly Hb values varied
over only a very narrow range over time, and
remained within the recommended Hb target
range of 10–12 g/dL [12, 13] at all study time
points.
Analysis of the dose ratio of DA to PEG-Epo
at switch indicated a broad range of dose ratios
across countries, perhaps reflective of the lack of
guidance in the product labels on the
appropriate starting dose ratio when switching
from PEG-Epo to DA. Despite the observed high
variability in dose ratio at switch, both doses
and Hb concentration values converged in the
post-switch period. As seen for the time course
of mean monthly Hb concentration, geometric
mean weekly DA doses at month 6 were similar
to the geometric mean weekly PEG-Epo doses in
the month prior to the switch. Decreasing DA
doses in the post-switch period were also
evident in the change in geometric mean dose
ratio over time, declining from 1.06 at switch to
0.88 at month 6. The return of ESA dose and Hb
concentration in the post-switch period towards
values similar to those in the month preceding
the switch suggests that physicians were able to
successfully titrate DA dose after switching, to
achieve the desired Hb concentration.
The dose-ratio subgroup analyses provided
additional support for the suggestion that
changes in the geometric mean weekly dose of
DA post-switch likely indicate titration by
physicians to maintain a stable Hb
concentration. The reduction in DA dose from
month 1 to month 3 post-switch was most
pronounced in patients switched at a dosing
ratio of [1.2 (i.e., a higher DA dose relative to
their pre-switch PEG-Epo dose), and this
subgroup showed the highest elevation in
mean Hb concentration by month 3. Across all
three dose-ratio subgroups, mean monthly Hb
converged within the range of 11.1–11.5 g/dL
by month 6, supporting the idea of dose
titration by physicians. This study was non-
interventional and was not intended to be
prescriptive of dose conversion ratios for
clinical practice; nevertheless, the findings of
the subgroup analyses may suggest that the
conversion ratio should be\1.2, in a population
clinically similar to the sample.
As previously noted, there are scant
published data on clinical parameters
associated with switching from PEG-Epo to
DA. The single previously published study of a
switch from PEG-Epo to DA, reported by Meier
in abstract form, compared Hb levels and ESA
doses 12 weeks pre-switch and 12 weeks post-
switch [17]. In this pilot evaluation, 21
hemodialysis patients from 3 centers were
switched from PEG-Epo QM to DA QW, Q2W,
or QM. After the switch, more patients reached
an Hb level of at least 11 g/dL than had done
during the pre-switch period (71.4% vs. 66.7%,
respectively) despite a dose decrease of 22%. On
the basis of these data, Meier suggested a
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conversion ratio in the range of 1 lg PEG-Epo to
0.7–0.9 lg DA. A detailed comparison between
the findings of TRANSFORM and Meier’s study
is precluded by the necessarily limited
information reported in the abstract, as well as
the differences in sample size and study period.
Nevertheless, both studies indicate that a dose
conversion ratio above 1.0 is not required when
switching from PEG-Epo to DA.
In the present study, excursions of Hb values
below the target range of 10–12 g/dL were more
common pre-switch compared to the post-
switch period. The onset and duration of Hb
excursions were not precisely calculable in this
observational study, because Hb concentration
was recorded per normal clinical practice rather
than at a protocol-prescribed frequency.
Results of TRANSFORM are not directly
comparable with those of the recently
published Aranesp Efficiency Relative to
Mircera (AFFIRM) study [16], an observational
study of European CKD patients switching from
DA to PEG-Epo (i.e., the reverse of the switch in
TRANSFORM), because the aims and analyses of
the two studies were different. In TRANSFORM,
dose ratio at switching was a secondary
outcome measure calculated across all patients
in the analysis set, independently of achieved
Hb level. In contrast, the primary goal of
AFFIRM was to calculate the population mean
maintenance dose conversion ratio, defined as
the dose ratio achieving comparable Hb level
between pre- and post-switch periods.
The TRANSFORM study has several strengths in
terms of helping to fill the information gap
regarding clinical parameters in CKD patients
switched from PEG-Epo to DA, most notably the
enrollment of a large cohort of hemodialysis
patients receiving real-world clinical
management for CKD-related anemia in several
European countries. However, there are
limitations in the ability to generalize the
findings of this study to the broader
hemodialysis patient population. Firstly,
although the study population was
heterogeneous, more than half of the sample was
drawn from a single country (France), so the
sample may not be as representative of other
European countries. Secondly, findings may not
be representative of patients experiencing clinical
worsening because the study enrolled
hemodialysis patients who were stable, as
defined by having not received chemotherapy or
a blood transfusion, or had surgery within the
14 weeks prior to the switch from PEG-Epo to DA.
Finally, since data were recorded as part of normal
clinical practice, not all data points were
guaranteed to be available for abstraction.
Despite this limitation, a high degree of
completeness was achieved, since this dialysis
population attended hemodialysis centers several
times per week, and the study assessments, which
were relevant to routine treatment, thus were
likely to be measured as a component of regular
clinical care.
The study was not designed to compare ESA
doses or to estimate a maintenance dose
conversion ratio—the primary outcome
measure focused solely on Hb, regardless of ESA
dose. Therefore, the dose data collected cannot
be extrapolated to the cost of either therapy and
do not permit accurate pharmacoeconomic
evaluation. Additionally, estimating the costs
associated with DA or PEG-Epo is difficult, given
the differences in center, hospital and country.
The lack of information on actual acquisition
cost by center (which can differ significantly
from list prices) would further complicate any
cost comparisons.
CONCLUSION
The TRANSFORM study showed that in this
cohort of EU hemodialysis patients who
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switched from PEG-Epo to DA (and who
completed 26 weeks of treatment with DA
post-switch) mean achieved Hb was
maintained within a narrow range over the
post-switch observation period. The
correspondence over time between mean Hb
and mean DA dose provides evidence that
physicians adjusted DA doses to achieve Hb
concentrations comparable to those attained
before switching.
TRANSFORM also indicated that higher DA
doses were not required in these patients
switching from PEG-Epo. There was
considerable variation in the dose ratio of DA
to PEG-Epo at the time of switching, which may
have been driven by the lack of label guidance
on dose conversion from PEG-Epo to DA, in the
absence of which dose conversion likely
reflected clinicians’ preferences. However,
there was no difference in mean weekly ESA
dose at the end of the post-conversion period
compared with pre-conversion dose, regardless
of patients’ dose ratio at switch.
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